Expression of transforming growth factor-α and hepatitis B surface antigen in human hepatocellular carcinoma tissues and its significance

Jing Zhang, Wen-Liang Wang, Qing Li, Qing Qiao

Jing Zhang, Wen-Liang Wang, Qing Li, Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi’an 710038, Shaanxi Province, China
Qing Qiao, Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, Shaanxi Province, China
Correspondence to: Jing Zhang, Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi’an 710038, Shaanxi Province, China
Telephone: +86-29-83375497 Fax: +86-29-83375497
Received: 2003-12-19 Accepted: 2004-01-08

Abstract

AIM: To evaluate the expression of transforming growth factor-alpha (TGF-α) and hepatitis B surface antigen (HBsAg) in human hepatocellular carcinoma (HCC) tissues and its significance.

METHODS: Seventy specimens of HCC tissues were detected by immunohistochemical method. Five specimens of normal human liver tissues were used as control.

RESULTS: The TGF-α positive expression rates in HCC and its surrounding tissues were 74.3%(52/70) and 88.1%(52/59), respectively. TGF-α positive granules were mainly in the cytoplasm and fewer existed on the karyotheca. The TGF-α positive expressing rate in well differentiated HCC was significantly higher than that in moderately and poorly differentiated HCC (P<0.05). The TGF-α positive expression also was observed in intrahepatic bile ducts (part of those were hyperplastic ducts). The HBsAg positive expression rates in HCC and its surrounding tissues were 21.4%(15/70) and 79.7%(47/59), respectively. TGF-α positive expression rates were compared by analysis of coherence. The expression of TGF-α and HBsAg were compared by analysis of coherence.

CONCLUSION: Hepatitis B virus infection is closely related with hepatocarcinogenesis. The overexpression of TGF-α in the liver seems to be associated with the regeneration of hepatocytes injured by HBsAg. The continued expression of TGF-α might lead to dysplasia of liver cells and development of HCC. Furthermore, TGF-α might play a role in morphogenesis and regeneration of intrahepatic bile ducts.

Zhang J, Wang WL, Li Q, Qiao Q. Expression of transforming growth factor-α and hepatitis B surface antigen in human hepatocellular carcinoma tissues and its significance. World J Gastroenterol 2004;10(6):830-833
http://www.wjgnet.com/1007-9327/10/830.asp

INTRODUCTION

Hepatocellular carcinoma (HCC) is a common malignant tumor in China with poor prognosis[1-8]. Substantial evidences have supported the concept that hepatitis B virus (HBV) infection is a causative factor for HCC[9-12]. The idiographic mechanisms of HBV in hepatocarcinogenesis had not been clearly defined yet. Transforming growth factor-alpha (TGF-α) is a multi-peptide, which can promote cellular proliferation and transformation[13-15]. The normal hepatocytes almost had no expression of TGF-α mRNA except the epitheliums of bile ducts in human normal liver tissues[16]. It was also thought to be an autocrine regulator of normal growth and regeneration in the rat liver. There was also a close relationship between TGF-α and hepatocarcinogenesis[17-19]. In order to find the relationship between TGF-α and HBV infection in hepatocarcinogenesis, the expression of TGF-α and HBsAg in HCC tissues was studied by immunohistochemical method. Such studies have been rarely reported in China.

MATERIALS AND METHODS

Specimens

Tissue samples were obtained from seventy cases of HCC in Xijing Hospital from January 1988 to January 1995. Among them, fifty-nine cases of HCC had surrounding tissues. Five cases of normal human liver tissues were obtained from autopsy (excluding liver disease). All specimens were fixed in 40 g/L methanal solution, embedded in wax, and cut into 5 μm thick serial sections.

Reagents and methods

Mouse anti-human TGF-α was purchased from Santa Cruz, UAS. Mouse anti-human HBsAg and SABC kit were purchased from Wuhan Boster Co. Ltd. The expression of TGF-α and HBsAg was detected by SABC immunohistochemical method. In the control group, the primary antibody was substituted by PBS or normal mouse serum. All paraffin embedded sections were deparaffinized and rehydrated, and pretreated for 20 min at 75 ℃ in a microwave oven. After being treated with 1 mL/L H2O2 for 30 min to block the endogenous peroxidase, the sections were incubated with 20 mL/L fetal calf serum for 30 min to reduce nonspecific binding. Then the primary HBsAg and TGF-α antibodies were applied to the sections and incubated at 4 ℃ overnight. The sections were subsequently incubated with goat anti mouse IgG at 37 ℃ for 30 min, followed by incubation with SABC at 37 ℃ for 30 min, and washed with DAB-H2O2 for 5-10 min and counterstained with hematoxylin. Results estimation: the specimens with no positive cells or positive cells <10% were negative (-); with light brownish yellow cells or positive cells between 10-50% were weakly positive (+); with deep brownish yellow cells or positive cells >50% were positive (+).

Statistical analysis

Chi-square test was used to analyse the results. The expression of TGF-α and HBsAg were compared by analysis of coherence.
RESULTS

The expression of TGF-α and HBsAg in HCC

The TGF-α positive expression rates in HCC and its surrounding tissues were 74.3%(52/70) and 88.1%(52/59), respectively. The positive cells mainly existed diffusely and fewer existed in foci. The positive stainings were like brown-yellow granules, and were mainly located in the cytoplasm and/or fewer located on the karyotheca (Figure 1). There was a prominent difference in TGF-α distribution between HCC and its surrounding tissues ($\chi^2=3.93, P<0.05$). The TGF-α positive expression rate in well differentiated HCC was significantly higher than that in moderately and poorly differentiated HCC ($\chi^2=9.11, P<0.05$, Table 1). TGF-α positive expression also was observed in intrahepatic bile ducts (part of those were hyperplastic ducts). In the five cases of normal liver tissues, TGF-α was undetectable in hepatocytes and bile ducts.

Table 1  TGF-α expression in different HCC differentiation

| Differentiation | n | Positive cases | Positive rate (%) |
|-----------------|---|---------------|-------------------|
| Well            | 15 | 15            | 100.0             |
| Moderately      | 48 | 34            | 70.8              |
| Poorly          | 7  | 3             | 42.9              |

The HBsAg positive expression rates in HCC and its surrounding tissues were 21.4%(15/70) and 79.7%(47/59), respectively. The positive cells mainly existed diffusely and fewer existed in foci. The positive stainings were like brown-yellow granules or floccules. They were located in the cytoplasm, inclusion and on the karyotheca (Figure 2). There was a prominent difference in HBsAg distribution between HCC and its surrounding tissues ($\chi^2=43.5, P<0.05$). HBsAg expression was negative in the five cases of normal liver tissues.

The PBS blank controls and normal mouse serum substituted controls were negative for immunohistochemical staining.

Relationship between TGF-α and HBsAg expression

There was not a prominent correlation between TGF-α and HBsAg expression in HCC tissues, but there was a prominent positive correlation between TGF-α and HBsAg expression in HCC surrounding tissues ($P<0.05, \gamma=0.34$, Table 2). TGF-α was usually existed with HBsAg in regenerated and/or dysplastic liver cells. These cells had increcent or double nucleus, prominent or anomalous nucleolus, high ratio of nucleus/ cytoplasm, etc. (Figures 3 and 4).

Table 2 Relation between TGF-α and HBsAg expression in HCC surrounding tissues

| TGF-α | HBsAg | HBsAg |
|-------|-------|-------|
| +     | 52    | 44    | 8     |
| -     | 7     | 3     | 4     |
| Total | 59    | 47    | 12    |

DISCUSSION

TGF-α was found in culture medium of fibroblasts transformed by some retroviruses in 1970s and nominated because of its ability to transform and induce the renal fibroblasts to proliferate. It is composed of 50 amino acid residues, with a 30% to 40% amino acid homology to epidermal growth factor (EGF), and binds the EGF receptor in the cellular membrane[20]. TGF-α was secreted by many transformed cells and involved in embryonic development. In human cancers, studies showed that TGF-α could serve as a tumor marker and as a marker for the malignant potential of a tumor[21]. Thus far, the types of carcinomas with which abnormal TGF-α expression has been associated include liver[22], gastrointestinal[23], breast[24], skin[25], lung[26], brain[27] and ovarian cancers[28]. TGF-α might play a role in the processes involved with tumor initiation and
growth. In cell lines, TGF-α has been found to be associated with autocrine and/or paracrine types of cellular growth initiation and with increased levels of oncogene expression\(^{26,30}\). It could promote the hepatocellular proliferation, differentiation, regeneration and tumor cell growth\(^{31}\). Transgenic mice that overexpressed TGF-α developed liver tumors between 12 and 15 months of age\(^{32}\). In our study, we found the TGF-α expression in the HCC and its surrounding tissues was significantly higher than that of normal liver tissues. The positive rate of TGF-α expression in well differentiated HCC was higher than that in moderately and poorly differentiated HCC. These may suggest the involvement of TGF-α in cellular transformation and provide a supporting evidence for the autocrine stimulation model. Increased expression of TGF-α might be the events of human primary hepatocarcinogenesis. In the later stages of HCC, there might be the other factors responsible for decreasing expression of TGF-α. Furthermore, we also found that intrahepatic bile ducts (part of these were hyperplasia ducts) were stained positive for TGF-α, suggesting that TGF-α might play a role in morphogenesis and regeneration of intrahepatic bile ducts.

Up to now, the close relationship among hepatitis B virus, liver cirrhosis and HCC has been approved\(^{32}\), but the mechanisms have not been clearly defined yet. One hypothesis is that chronic HBV infection caused prolonged liver cellular injury, inflammation and cellular death. The hepatic regeneration after liver necrosis, along with DNA damage from genotoxic agents generated during the inflammatory response, was thought to increase the risk of HCC development\(^{33}\). Because of HBV replication in liver cells, HBV major envelope protein, HBsAg was often overexpressed. It accumulated to toxic levels in the endoplasmic reticulum of hepatocytes. This could lead to the chronic injury of hepatocytes, inflammation and cellular death by immune reaction\(^{34}\). In our study, we found the positive expression rate of HBsAg in the HCC surrounding tissues was higher than that of HCC tissues. There was a prominent difference in HBsAg distribution between the HCC and its surrounding tissues ($\chi^2 = 43.5, P<0.05$). This suggested HBsAg might have more closely involved in hepatic cells injury than in hepatocarcinogenesis.

TGF-α is a potent mitogen for hepatocytes. It can induce hepatocytes to proliferate. Though we did not found the correlation between TGF-α and HBsAg in the HCC tissues, we found there was a prominent positive correlation between TGF-α and HBsAg in the HCC surrounding tissues. These cells had increscent or double nucleus, prominent or anomalous nucleolus and high ratio of nucleus/cytoplasm, etc. These data suggest that TGF-α overexpression in the liver seems to be associated with the hepatocellular regeneration injured by HBsAg. HBsAg may up-regulate the expression of TGF-α. Continued overexpression of TGF-α could lead to hepatocellular proliferation and dysplasia. These might have contributed to hepatocarcinogenesis and HCC growth.

REFERENCES

1 Zhao H, Zhou KR, Yan FH. Role of multiphase scans by multiview-detector helical CT in detecting small hepatocellular carcinoma. World J Gastroenterol 2003; 9: 2198-2201
2 Li QL, Wang WL, Zhang XH, Yan W. Expression of hsMAD in human hepatocellular carcinoma and its significance. Shijie Hua ren Xiaohua Zazhi 2003; 11: 1326-1329
3 Ge NL, Ye SL, Zheng N, Sun RX, Liu YK, Tang ZY. Prevention of hepatocellular carcinoma in mice by IL-2 and B7-1 gene co-transfected liver cell vaccines. World J Gastroenterol 2003; 9: 2182-2185
4 Wang W, Yang LY, Yang ZL, Huang GW, Lu WQ. Expression and significance of RhoC gene in hepatocellular carcinoma. World J Gastroenterol 2003; 9: 1950-1953
5 Jin ZY, Cheng RX, Zheng CL, Zheng H. Expression of PTGG and c-myc gene in human primary hepatocellular carcinoma. Shijie Hua ren Xiaohua Zazhi 2003; 11: 1677-1681
6 Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol 2003; 9: 1895-1899
7 Huang J, Cai MY, Wei DP. HLA class I expression in primary hepatocellular carcinoma. World J Gastroenterol 2002; 8: 654-657
8 Hsu CY, Chu CH, Lin SC, Yang FS, Yang TL, Chang KM. Concomitant hepatocellular adenoma and adenomatous hyperplasia in a patient without cirrhosis. World J Gastroenterol 2003; 9: 627-630
9 Ma CH, Sun WS, Tian PK, Gao LF, Liu SX, Wang XY, Zhang LN, Cao YL, Han LH, Liang XH. A novel HBV antisense RNA gene delivery system targeting hepatocellular carcinoma. World J Gastroenterol 2003; 9: 463-467
10 Shen L, Zhang HY, Zhang ZJ, Li JY, Chen MQ, Yang WB, Huang R. Detection of HBV, PCNA and GST-π in hepatocellular carcinoma and chronic liver diseases. World J Gastroenterol 2003; 9: 459-462
11 Dai ZY, Xu QH, Li G, Ma HH, Tang ZH, Shu X, Yao JY. Study on X gene mutation of hepatitis B virus from patients with hepatocellular carcinoma. Shijie Hua ren Xiaohua Zazhi 2003; 11: 1349-1352
12 Tang ZY. Hepatocellular carcinoma--cause, treatment and metastasis. World J Gastroenterol 2003; 7: 445-454
13 Awwad RA, Sergina N, Yang H, Zlobber B, Willson JK, Zborowska E, Humphrey LE, Fan R, Ko TC, Brattain MG, Howell GM. The role of transforming growth factor alpha in determining growth factor independence. Cancer Res 2003; 63: 4731-4738
14 Cianna P, Ghisletti S, Mussi P, Eberini I, Vekteo G, Maggi A. Estrogen receptor alpha, a molecular switch converting transforming growth factor-alpha-mediated proliferation into differentiation in neuroblastoma cells. J Biol Chem 2003; 278: 31737-31744
15 Grasl-Kraupp B, Schausberger E, Hufnagl K, Gerner C, Low- Baselli A, Rossmanith W, Parzefall W, Schulte-Hermann R. A novel mechanism for mitogenic signaling via pro-transforming growth factor alpha within hepatocyte nuclei. Hepatology 2002; 35: 1372-1380
16 Derynick R, Goeddel DV, Ullrich A, Guttermann JU, Williams RD, Bringman TS, Berger WH. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 1987; 47: 707-712
17 Thorgerisson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346
18 Matsumoto T, Takagi H, Mori M. Androgen dependency of hepatocarcinogenesis in TGFalpha transgenic mice. Liver 2000; 20: 228-233
19 Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SS. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000; 275: 8806-8811
20 Todaro GJ, Frying C, De Larco JE. Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors. Proc Natl Acad Sci USA 1980; 77: 5258-5262
21 Grigioni WF. Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer 2002; 94: 647-657
22 Vail ME, Pierce RH, Fausto N. Bcl-2 delays and alters hepatic carcinogenesis induced by transforming growth factor alpha. Cancer Res 2001; 61: 594-601
23 Sawhney RS, Sharma B, Humphrey LE, Brattain MG. Integrin alpha2 and extracellular signal-regulated kinase are functionally linked in highly malignant autocrine transforming growth factor-alpha driven colon cancer cells. J Biol Chem 2003; 278: 18981-18989
24 More E, Fellner T, Doppelmayer H, Hauser-Kronberger C, Dandachi N, Obrist P, Sandhofer F, Paulweber B. Activation of the MAP kinase pathway induces chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) expression in human breast cancer cell lines. J Endocrinol 2003; 176: 83-94
25 Wu M, Putti TC, Bhuiya TA. Comparative study in the expression of p53, EGFR, TGF-alpha, and cyclinD1 in verrucous carcinoma, verrucous hyperplasia, and squamous cell carcinoma of head and neck region. *Appl Immunohistochem Mol Morphol* 2002; **10**: 351-356

26 Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, Hamburger DC, Grizzle WE. Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. *Clin Cancer Res* 2002; **8**: 734-744

27 Zhou R, Skalli O. Identification of cadherin-11 down-regulation as a common response of astrocytoma cells to transforming growth factor-alpha. *Differentiation* 2000; **66**: 165-172

28 Doraiswamy V, Parrott JA, Skinner MK. Expression and action of transforming growth factor alpha in normal ovarian surface epithelium and ovarian cancer. *Biol Reprod* 2000; **63**: 789-796

29 Masuda M, Suzui M, Lim JT, Deguchi A, Soh JW, Weinstein IB. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. *J Exp Ther Oncol* 2002; **2**: 350-359

30 Wong YC, Wang YZ. Growth factors and epithelial-stromal interactions in prostate cancer development. *Int Rev Cytol* 2000; **199**: 65-116

31 Sohda T, Iwata K, Tsutsu N, Kamimura S, Shijo H, Sakisaka S. Increased expression of transforming growth factor-alpha in a patient with recurrent hepatocellular carcinoma following partial hepatectomy. *Pathology* 2001; **33**: 511-514

32 Yuen MF, Lai CL. Specific considerations in the design of hepatitis B virus clinical studies in the far East. *Methods Mol Med* 2004; **96**: 457-464

33 Jakubczak JL, Chisari FV, Merlino G. Synergy between transforming growth factor alpha and hepatitis B virus surface antigen in hepatocellular proliferation and carcinogenesis. *Cancer Res* 1997; **57**: 3606-3611

34 Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Pinkert CA, Brinster RL, Palmiter RD. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. *Cell* 1989; **59**: 1145-1156

*Edited by* Gupta MK  *Proofread by* Xu FM